Limits...
The expressions of bHLH gene HES1 and HES5 in advanced ovarian serous adenocarcinomas and their prognostic significance: a retrospective clinical study.

Wang X, Fu Y, Chen X, Ye J, Lü B, Ye F, Lü W, Xie X - J. Cancer Res. Clin. Oncol. (2009)

Bottom Line: Of those, Overall survival period of patients with HES1 low-expression was significantly longer than that of those with high-expression (chi(2) = 4.049, P = 0.044).Univariate analysis and multivariate Cox regression model did not show that HES1 or HES5 expression was a factor associated with survival of advanced ovarian serous adenocarcinoma patients.The expressions of bHLH gene HES1 and HES5 are increased in advanced ovarian serous adenocarcinomas, and HES1 high-expression probably is a potential poor prognostic factor for the patients.

View Article: PubMed Central - PubMed

Affiliation: Women's Reproductive Health Laboratory of Zhejiang Province, Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, 310006 Hangzhou, China.

ABSTRACT

Purpose: Notch signaling was recently found to be associated with prognosis of some cancers. The aim of the study is to investigate significance of the expression of HES1/HES5 protein, downstream effectors of Notch, in prognosis of the patients with advanced ovarian epithelial cancers.

Methods: Formalin-fixed, paraffin embedded tissues and clinic-pathological parameters from 61 patients with FIGO stage IIIc-IV ovarian serous adenocarcinoma were collected, the expression of HES1 and HES5 protein were immunohistochemically detected, and the association of HES1 and HES5 expression with survival of the patients were analyzed.

Results: The expressions of both HES1 and HES5 in adenocarcinoma were significantly higher than those in adenoma and normal control (chi(2) = 32.915, P = 0.000 and chi(2) = 46.863, P = 0.000 respectively). Overall survival and disease-free period were longer in HES1 low-expression patients (median 43.0 and 22.0 months) than those in high-expression patients (median 24.0 and 14.5 months). Of those, Overall survival period of patients with HES1 low-expression was significantly longer than that of those with high-expression (chi(2) = 4.049, P = 0.044). Univariate analysis and multivariate Cox regression model did not show that HES1 or HES5 expression was a factor associated with survival of advanced ovarian serous adenocarcinoma patients.

Conclusions: The expressions of bHLH gene HES1 and HES5 are increased in advanced ovarian serous adenocarcinomas, and HES1 high-expression probably is a potential poor prognostic factor for the patients.

Show MeSH

Related in: MedlinePlus

Overall and disease-free survivals of the patients with HES5 low-expression and high-expression. No differences of overall or disease-free survival between HES5 low-expression and high-expression were found
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2874490&req=5

Fig3: Overall and disease-free survivals of the patients with HES5 low-expression and high-expression. No differences of overall or disease-free survival between HES5 low-expression and high-expression were found

Mentions: All 61 patients were followed up for 12–108 months, of those, 11 patients were lost. In remained 50 patients, 39 patients relapsed and seven underwent second operation, 11 did not relapse till end of follow-up. Median overall and disease-free survival period for the patients with HES1 low-expressions were 43.0 and 22.0 months, while those with high-expressions were only 24.0 and 14.5 months respectively. Overall survival period in patients with HES1 low-expression was significantly longer than that in those with high-expression (χ2 = 4.049, P = 0.044), but no differences of overall and disease-free survival periods were found between patients with HES5 low-expression and high-expression, as shown in Fig. 2 and 3. Both univariate analysis and multivariate Cox regression model did not show that HES1 or HES5 expression was a factor associated with survival of advanced ovarian serous adenocarcinoma patients, as shown in Tables 3 and 4.Fig. 2


The expressions of bHLH gene HES1 and HES5 in advanced ovarian serous adenocarcinomas and their prognostic significance: a retrospective clinical study.

Wang X, Fu Y, Chen X, Ye J, Lü B, Ye F, Lü W, Xie X - J. Cancer Res. Clin. Oncol. (2009)

Overall and disease-free survivals of the patients with HES5 low-expression and high-expression. No differences of overall or disease-free survival between HES5 low-expression and high-expression were found
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2874490&req=5

Fig3: Overall and disease-free survivals of the patients with HES5 low-expression and high-expression. No differences of overall or disease-free survival between HES5 low-expression and high-expression were found
Mentions: All 61 patients were followed up for 12–108 months, of those, 11 patients were lost. In remained 50 patients, 39 patients relapsed and seven underwent second operation, 11 did not relapse till end of follow-up. Median overall and disease-free survival period for the patients with HES1 low-expressions were 43.0 and 22.0 months, while those with high-expressions were only 24.0 and 14.5 months respectively. Overall survival period in patients with HES1 low-expression was significantly longer than that in those with high-expression (χ2 = 4.049, P = 0.044), but no differences of overall and disease-free survival periods were found between patients with HES5 low-expression and high-expression, as shown in Fig. 2 and 3. Both univariate analysis and multivariate Cox regression model did not show that HES1 or HES5 expression was a factor associated with survival of advanced ovarian serous adenocarcinoma patients, as shown in Tables 3 and 4.Fig. 2

Bottom Line: Of those, Overall survival period of patients with HES1 low-expression was significantly longer than that of those with high-expression (chi(2) = 4.049, P = 0.044).Univariate analysis and multivariate Cox regression model did not show that HES1 or HES5 expression was a factor associated with survival of advanced ovarian serous adenocarcinoma patients.The expressions of bHLH gene HES1 and HES5 are increased in advanced ovarian serous adenocarcinomas, and HES1 high-expression probably is a potential poor prognostic factor for the patients.

View Article: PubMed Central - PubMed

Affiliation: Women's Reproductive Health Laboratory of Zhejiang Province, Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, 310006 Hangzhou, China.

ABSTRACT

Purpose: Notch signaling was recently found to be associated with prognosis of some cancers. The aim of the study is to investigate significance of the expression of HES1/HES5 protein, downstream effectors of Notch, in prognosis of the patients with advanced ovarian epithelial cancers.

Methods: Formalin-fixed, paraffin embedded tissues and clinic-pathological parameters from 61 patients with FIGO stage IIIc-IV ovarian serous adenocarcinoma were collected, the expression of HES1 and HES5 protein were immunohistochemically detected, and the association of HES1 and HES5 expression with survival of the patients were analyzed.

Results: The expressions of both HES1 and HES5 in adenocarcinoma were significantly higher than those in adenoma and normal control (chi(2) = 32.915, P = 0.000 and chi(2) = 46.863, P = 0.000 respectively). Overall survival and disease-free period were longer in HES1 low-expression patients (median 43.0 and 22.0 months) than those in high-expression patients (median 24.0 and 14.5 months). Of those, Overall survival period of patients with HES1 low-expression was significantly longer than that of those with high-expression (chi(2) = 4.049, P = 0.044). Univariate analysis and multivariate Cox regression model did not show that HES1 or HES5 expression was a factor associated with survival of advanced ovarian serous adenocarcinoma patients.

Conclusions: The expressions of bHLH gene HES1 and HES5 are increased in advanced ovarian serous adenocarcinomas, and HES1 high-expression probably is a potential poor prognostic factor for the patients.

Show MeSH
Related in: MedlinePlus